What Is Stargardt's Disease / Macular Dystrophy?
Stargardt's disease (also called Stargardt's macular dystrophy or fundus flavimaculatus) is the most common degenerative retinal dystrophy in children and young adults, affecting approximately 1 in 8,000–10,000 people worldwide. It is caused by mutations in the ABCA4 gene, which codes for a protein involved in processing vitamin A in the retina. When this protein is absent or dysfunctional, a toxic by-product called A2E accumulates in the retinal pigment epithelium (RPE) cells, causing progressive cell death and central vision loss. Macular dystrophy is a broader term for a group of degenerative conditions affecting the macula, of which Stargardt's is the most common. Inheritance is typically autosomal recessive — meaning both parents must carry the gene variant for a child to be affected.
Common Symptoms
Stargardt's disease typically presents in the first or second decade of life, though onset can occur at any age. Common symptoms include: progressive blurring or loss of central vision — often the first noticeable symptom; difficulty reading or seeing fine detail; visual distortions or a grey, black, or hazy spot in the centre of vision (central scotoma); light sensitivity (photophobia) — many patients find bright environments particularly challenging; difficulty adapting from bright to dim light; reduced colour discrimination; and gradual reduction in visual acuity, often progressing to legal blindness (6/60 or worse) in adulthood. Peripheral vision is typically preserved. The rate of progression varies significantly between individuals.
Research & Treatment Development
Stargardt's disease and macular dystrophy are among the most actively researched areas in ophthalmology. Current research and treatment development includes: targeted molecular therapies targeting the ABCA4 mutation — several Phase I/II clinical trials using adeno-associated virus (AAV) vectors are ongoing; advanced medical innovation approaches exploring retinal cell protection and RPE regeneration; visual cycle modulators — small molecules aimed at reducing A2E accumulation by slowing the visual cycle (including emixustat and ALK1 inhibitors); retinal cell protection methods using antioxidants and neuroprotective agents; vision restoration technologies including electronic retinal prostheses; advanced diagnostic imaging using autofluorescence, OCT, and full-field electroretinography (ERG); and personalised eye care research combining genetic testing with tailored treatment protocols.
Our Approach at Med Cure Centre
Med Cure Centre is a specialist centre for the treatment and management of Stargardt's disease and degenerative macular dystrophies. Our ophthalmology team, led by Dr. Pallavee R. Goswami (26 Years Experience in Ophthalmology), has extensive experience managing patients with these rare conditions. We offer thorough clinical assessment including genetic counselling and advanced retinal imaging. Our treatment protocols are personalised based on genetic profile, disease stage, and visual function. We treat patients of all ages including children and young adults, and have served patients from over 50 countries worldwide. We are realistic and transparent about outcomes — our primary goal is to slow progression and preserve remaining vision for as long as possible.
📄 Scientific References
- National Institutes of Health (NIH) — National Library of Medicine. PubMed database. pubmed.ncbi.nlm.nih.gov
- World Health Organization (WHO) — Neurological Disorders & Eye Health Resources. who.int
- American Academy of Ophthalmology / Neurology — Clinical guidelines and disease statistics. aao.org